Related Experiment Video
Updated: May 29, 2026
10:13
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Published on: June 9, 2017
A polymorphism-specific "memory" mechanism in the β(2)-adrenergic receptor
Andrea Ahles1, Francesca Rochais, Torsten Frambach
1Institute of Pharmacology and Toxicology, Technische Universitaet Muenchen (TUM), Biedersteiner Strasse 29, 80802 Munich, Germany.
Science Signaling
|August 27, 2011
Summary
Genetic variations in G protein-coupled receptors alter their signaling dynamics. Specific β(2)-adrenergic receptor (β(2)AR) variants show changed activation speeds, impacting drug responses.
Area of Science:
- Pharmacology
- Molecular Biology
- Biochemistry
Background:
- Signaling via G protein-coupled receptors (GPCRs) is crucial for cellular communication.
- Genetic polymorphisms in GPCRs can influence receptor function and drug efficacy.
- The β(2)-adrenergic receptor (β(2)AR) is a key target for various medications.
Purpose of the Study:
- To investigate how genetic variations affect the activation kinetics of the β(2)AR.
- To determine if altered activation kinetics correlate with receptor efficacy.
- To understand the role of receptor phosphorylation in these changes.
Main Methods:
- Utilized fluorescence resonance energy transfer (FRET) to monitor receptor activation in real-time.
- Compared the activation kinetics of different β(2)AR polymorphic variants.
- Assessed the impact of G protein-coupled receptor kinase (GRK) phosphorylation on activation dynamics.
Main Results:
- Repeated activation of the β(2)AR led to altered activation kinetics.
- Polymorphic variants exhibited distinct changes in activation kinetics, mirroring their cyclic adenosine 3',5'-monophosphate (cAMP) generation efficacies.
- More efficacious variants showed faster activation kinetics, while less efficacious variants showed slower kinetics upon repeated stimulation.
- These kinetic alterations were dependent on receptor phosphorylation by GRKs.
Conclusions:
- The β(2)AR possesses an intrinsic, polymorphism-specific property that modifies its activation kinetics upon sustained stimulation.
- Divergent activation kinetics of β(2)AR variants may explain individual variations in drug responses.
- Understanding these molecular mechanisms can inform personalized medicine approaches.
Related Concept Videos
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:27Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
01:31Sympathetic Signaling
Sympathetic signaling, a vital part of the autonomic nervous system, plays a crucial role in mobilizing the body's resources in response to stress or emergencies. It involves the transmission of nerve impulses from sympathetic preganglionic fibers to postganglionic fibers. This results in the release of specific neurotransmitters and activation of adrenergic receptors.
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
Sympathetic preganglionic fibers release the neurotransmitter acetylcholine (ACh) onto the ganglionic neurons in the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...